I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
I wholeheartedly concur! The current trajectory appears...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |